Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: Post hoc analysis of the DELIVER trial

被引：2
|
作者：
Barbanti, Piero [1 ]
Awad, Susanne F. [2 ]
Regnier, Stephane A. [2 ]
Lee, Xin Ying [2 ]
Goadsby, Peter J. [3 ,4 ]
机构：
[1] IRCCS San Raffaele, Headache & Pain Unit, Milan, Italy
[2] H Lundbeck & Co AS, Valby, Denmark
[3] Kings Coll London, NIHR Kings Clin Res Facil, London, England
[4] Kings Coll London, Headache Grp, London, England
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202965
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P13-12.012
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study
    Piero Barbanti
    Peter J. Goadsby
    Giorgio Lambru
    Anders Ettrup
    Cecilie Laurberg Christoffersen
    Mette Krog Josiassen
    Ravinder Phul
    Bjørn Sperling
    The Journal of Headache and Pain, 2022, 23
  • [32] Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis PROMISE-1 and PROMISE-2
    Ashina, M.
    McAllister, P.
    Cady, R.
    Hirman, J.
    Ettrup, A.
    HEADACHE, 2021, 61 : 123 - 123
  • [33] Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction A Post Hoc Analysis of the DELIVER Trial
    Vardeny, Orly
    Desai, Akshay S.
    Jhund, Pardeep S.
    Fang, James C.
    Claggett, Brian
    de Boer, Rudolf A.
    Hernandez, Adrian F.
    Inzucchi, Silvio E.
    Kosiborod, Mikhail N.
    Lam, Carolyn S. P.
    Martinez, Felipe A.
    Shah, Sanjiv J.
    Mc Causland, Finnian R.
    Petrie, Mark C.
    Vaduganathan, Muthiah
    McMurray, John J. V.
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2024, 9 (03) : 283 - 289
  • [34] Efficacy and Safety of Eptinezumab in Patients With Migraine and Self-Reported Aura: Post Hoc Analysis PROMISE-1 and PROMISE-2
    Ashina, M.
    McAllister, P.
    Cady, R.
    Hirman, J.
    Ettrup, A.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 77 - 77
  • [35] Efficacy and Safety of Eptinezumab in Patients With Migraine and Self-Reported Aura: Post Hoc Analysis PROMISE-1 and PROMISE-2
    Ashina, M.
    McAllister, P.
    Cady, R.
    Hirman, J.
    Ettrup, A.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 51 - 51
  • [36] Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
    Ashina, Messoud
    McAllister, Peter
    Cady, Roger
    Hirman, Joe
    Ettrup, Anders
    CEPHALALGIA, 2022, 42 (08) : 696 - 704
  • [37] Impact of Monthly Headache Day Frequency on Work Productivity and Impairment in Non-Work Activities among Persons with Migraine: Results from the Migraine in America Symptoms and Treatment Study
    Munjal, S.
    Singh, P.
    Bensimon, L.
    Reed, M. L.
    Bostic, R.
    Buse, D.
    Lipton, R. B.
    HEADACHE, 2019, 59 : 190 - 191
  • [38] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab
    Aurora, Sheena
    Oakes, Tina
    Zhang, Qi
    Ahl, Jonna
    Martinez, James
    NEUROLOGY, 2017, 88
  • [39] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab
    Aurora, Sheena
    Oakes, Tina
    Zhang, Qi
    Ahl, Jonna
    Martinez, James
    NEUROLOGY, 2017, 88
  • [40] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab
    Aurora, S. K.
    Oakes, T. M.
    Zhang, Q.
    Ahl, J.
    Martinez, J. M.
    HEADACHE, 2017, 57 : 182 - 183
12345